Startek (SRT) Stock Price, News & Analysis

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Startek in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SRT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SRT, but not buy additional shares or sell existing shares.
View SRT analyst ratings or view top-rated stocks.

2 brokerages have issued 12-month price targets for Startek's shares. Their SRT share price targets range from $4.00 to $5.50. On average, they predict the company's stock price to reach $4.75 in the next twelve months. This suggests a possible upside of 7.5% from the stock's current price.
View analysts price targets for SRT or view top-rated stocks among Wall Street analysts.

Startek, Inc. (NYSE:SRT) posted its quarterly earnings data on Tuesday, November, 2nd. The business services provider reported $0.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.04 by $0.03. The business services provider earned $172.79 million during the quarter, compared to analyst estimates of $162.31 million. Startek had a negative net margin of 5.81% and a positive trailing twelve-month return on equity of 12.22%. During the same period last year, the company posted $0.01 earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Startek investors own include Amicus Therapeutics (FOLD), KeyCorp (KEY), SentinelOne (S), Vishay Intertechnology (VSH), Huntington Bancshares (HBAN), Kindred Biosciences (KIN), Mitek Systems (MITK), Pfizer (PFE) and